Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 20 for:    Food Allergy | Dallas, Texas, U.S.
Previous Study | Return to List | Next Study

FARE Peanut SLIT and Early Tolerance Induction (FARE/SLIT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02304991
Recruitment Status : Completed
First Posted : December 2, 2014
Results First Posted : December 16, 2021
Last Update Posted : January 10, 2022
Sponsor:
Collaborators:
Food Allergy Research & Education
National Center for Complementary and Integrative Health (NCCIH)
University of Texas Southwestern Medical Center
Information provided by (Responsible Party):
University of North Carolina, Chapel Hill

Brief Summary:

Primary Objective: To determine if 36 months of peanut SLIT as an early intervention in subjects ages 1 to 4 years induces clinical desensitization. The primary outcome of this objective will be a statistically significant difference in challenge scores between the treatment group versus the placebo group during DBPCFC (Double blind placebo controlled food challenge) performed after 36 months of peanut SLIT (desensitization). Challenge scores are measured by the amount of peanut protein participants are able to ingest successfully without symptoms of an allergic reaction. [Time Frame: Baseline, 36 months]

Secondary Objectives:

A secondary outcome of this objective will be a statistically significant difference in the challenge score of the treatment group versus the placebo group during the DBPCFC performed 3 months after discontinuing therapy (tolerance).

To examine the change in immune parameters associated with peanut SLIT and the development of clinical tolerance. Through this objective, the investigators will seek to understand the molecular processes by which SLIT affects the immune system through evaluation of immune mechanisms in relationship to clinical findings of desensitization and tolerance. The investigators will delineate the impact of peanut SLIT on the subsequent cellular and humoral responses to peanut protein.

[Time Frame: Baseline, 39 months]


Condition or disease Intervention/treatment Phase
Peanut Hypersensitivity Food Allergy Food Hypersensitivity Peanut Allergy Drug: Liquid Peanut Extract Drug: Placebo Glycerin SLIT Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Peanut Sublingual Immunotherapy Induction of Clinical Tolerance of Newly Diagnosed Peanut Allergic 12 to 48 Month Old Children
Actual Study Start Date : January 2015
Actual Primary Completion Date : December 31, 2020
Actual Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Allergy

Arm Intervention/treatment
Experimental: Peanut (liquid peanut extract) SLIT
After the entry DBPCFC, subjects will be randomized 1:1 to active or placebo drug product. Subjects randomized to peanut SLIT therapy will dose for 36 months and undergo a second DBPCFC. The subjects will stop dosing for three months and repeat a DBPCFC at 39 months.
Drug: Liquid Peanut Extract
5000mcg/ml peanut protein
Other Name: SLIT

Placebo Comparator: Placebo Glycerin SLIT
After the entry DBPCFC, subjects will be randomized 1:1 to active or placebo drug product. Subjects randomized to placebo glycerin SLIT will dose for 36 months and undergo a second DBPCFC. The subjects will stop dosing for three months and repeat a DBPCFC at 39 months.
Drug: Placebo Glycerin SLIT
pure glycerinated saline solution with caramel coloring to match color
Other Name: SLIT




Primary Outcome Measures :
  1. Desensitization After 36 Months of Peanut SLIT or Placebo SLIT [ Time Frame: 36 months ]

    The primary outcome of this study will be a statistically significant difference in the challenge score of the treatment group versus the placebo group during DBPCFC after 36 months of peanut SLIT (desensitization).

    DBPCFC Challenge Score scale:

    Minimum score = 0; Maximum score = 7 Larger challenge score equals more successful desensitization. 0mg = 0; 3mg = 1; 13mg = 2; 43mg = 3; 143mg = 4; 443mg = 5; 1443mg = 6; and 4443mg = 7.



Secondary Outcome Measures :
  1. Tolerance 3 Months After Discontinuing Peanut SLIT or Placebo SLIT [ Time Frame: 39 months ]

    A secondary outcome of this study will be a statistically significant difference in the challenge score of the treatment group versus the placebo group during the DBPCFC performed 3 months after discontinuing therapy (tolerance).

    DBPCFC Challenge Score scale:

    Minimum score = 0; Maximum score = 7 Larger challenge score equals more successful desensitization. 0mg = 0; 3mg = 1; 13mg = 2; 43mg = 3; 143mg = 4; 443mg = 5; 1443mg = 6; and 4443mg = 7.


  2. Change in Immune Parameters With Peanut SLIT Versus Placebo SLIT (Peanut-specific IgE) [ Time Frame: 0 months to 36 months ]

    The change in immune parameters over time associated with the induction of clinical desensitization compared to the failure to achieve clinical desensitization.

    Peanut-specific IgE measured at baseline and at completion of peanut SLIT (36 months). Change in IgE reported in kUA/L.


  3. Change in Immune Parameters With Peanut SLIT Versus Placebo SLIT (Peanut-specific IgG4) [ Time Frame: 0 months to 36 months ]

    The change in immune parameters over time associated with the induction of clinical desensitization compared to the failure to achieve clinical desensitization.

    Peanut-specific IgG4 measured at baseline and at completion of peanut SLIT (36 months). Change in IgG4 reported in mg/L.


  4. Change in Immune Parameters With Peanut SLIT Versus Placebo SLIT (Peanut Skin Prick Test) [ Time Frame: 0 months to 36 months ]

    The change in immune parameters over time associated with the induction of clinical desensitization compared to the failure to achieve clinical desensitization.

    Peanut-skin prick test measured at baseline and at completion of peanut SLIT (36 months). Change in skin prick test reported in mm wheal diameter.


  5. Number of Participants Experiencing Serious Adverse Events With Peanut SLIT Versus Placebo SLIT [ Time Frame: 39 months ]
    Incidence of all serious adverse events from initial enrollment through the end of the 3 month avoidance period reported as the number of participants experiencing a serious adverse event.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Months to 48 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent from participant's parent/guardian.
  • Age 12-48 months of either sex, any race, any ethnicity.
  • A peanut allergy diagnosis with a convincing clinical history of peanut allergy and a serum peanut-specific IgE [UniCAP] > 0.35 kUA/L AND a positive skin prick test to peanut (>3 mm than the negative control) OR are sensitized to peanut (based on a serum IgE [UniCAP] to peanut of > 5 kUA/L) AND a positive skin prick test to peanut (> 3 mm than the negative control) and no known history of ingestion of peanut.
  • A positive DBPCFC to 1000 mg of peanut at enrollment.

Exclusion Criteria:

  • History of severe anaphylaxis to peanut, defined as hypoxia, hypotension, or neurologic compromise (cyanosis or peripheral capillary oxygen saturation (SpO2) < 92% at any stage, hypotension, confusion, collapse or loss of consciousness).
  • Participation in any interventional study for the treatment of food allergy in the past 6 months.
  • Known oat, wheat, or glycerin allergy.
  • Eosinophilic or other inflammatory (e.g. celiac) gastrointestinal disease.
  • Severe asthma (2007 NHLBI Criteria Steps 5 or 6 - Appendix 2).
  • Inability to discontinue antihistamines for skin testing and DBPCFCs.
  • Use of omalizumab or other non-traditional forms of allergen immunotherapy (e.g., oral or sublingual) or immunomodulator therapy (not including corticosteroids) or biologic therapy within the past year.
  • Use of beta-blockers (oral), angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARB) or calcium channel blockers.
  • Significant medical condition (e.g., liver, kidney, gastrointestinal, cardiovascular, hematologic, or pulmonary disease) which would make the subject unsuitable for induction of food reactions.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02304991


Locations
Layout table for location information
United States, North Carolina
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27599
United States, Texas
University of Texas Southwestern Medical Center
Dallas, Texas, United States, 75235
Sponsors and Collaborators
University of North Carolina, Chapel Hill
Food Allergy Research & Education
National Center for Complementary and Integrative Health (NCCIH)
University of Texas Southwestern Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Wesley Burks, MD University of North Carolina, Chapel Hill
  Study Documents (Full-Text)

Documents provided by University of North Carolina, Chapel Hill:
Layout table for additonal information
Responsible Party: University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier: NCT02304991    
Other Study ID Numbers: 14-0648
R01AT004435-07 ( U.S. NIH Grant/Contract )
First Posted: December 2, 2014    Key Record Dates
Results First Posted: December 16, 2021
Last Update Posted: January 10, 2022
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by University of North Carolina, Chapel Hill:
Peanut
Food Allergy
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypersensitivity
Food Hypersensitivity
Peanut Hypersensitivity
Immune System Diseases
Hypersensitivity, Immediate
Nut and Peanut Hypersensitivity
Glycerol
Cryoprotective Agents
Protective Agents
Physiological Effects of Drugs